Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Child-Resistant Packaging In The Works For More OTC Cold Products – CHPA

This article was originally published in The Tan Sheet

Executive Summary

Leading OTC drug firms will voluntarily expand the use of child-resistant packaging to all cough/cold products while also considering new child-proof package designs to reduce the risk of accidental ingestion, the Consumer Healthcare Products Association says

You may also be interested in...



Warnings Not To Give Young Children Cough/Cold OTCs Still Go Unheeded

Four in 10 parents said they administered OTC cough and cold products to children younger than 4 years even though labeling says not to use in this age group, according to a national poll. The finding suggests more education is necessary to reduce confusion and noncompliance.

Warnings Not To Give Young Children Cough/Cold OTCs Still Go Unheeded

Four in 10 parents said they administered OTC cough and cold products to children younger than 4 years even though labeling says not to use in this age group, according to a national poll. The finding suggests more education is necessary to reduce confusion and noncompliance.

Campaign Targets Unsupervised Pediatric Drug Ingestion

The Consumer Healthcare Products Association, the Centers for Disease Control and Prevention and a public-private safe-medication initiative launch the “Up and Away and Out of Sight” campaign to educate caregivers about how to stop curious children from consuming drugs without supervision.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101316

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel